Navigation Links
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy
Date:5/22/2008

Establishes Preferred Dose for Optimal Efficacy and Tolerability; Study Goals and Secondary Endpoints Met

SYDNEY, Australia and BEDMINSTER, N.J., May 22 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today additional Phase 3 data for Q8003IR establishing a 12mg/8mg morphine and oxycodone combination as the preferred dose for optimal efficacy and tolerability.

"While the initial Phase 3 efficacy data demonstrated statistically significant pain reduction activity of Q8003IR at all dose levels, further analysis suggests that the 12mg/8mg dose delivers the best analgesic effect and tolerability profile," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "These data confirm that our patented dual opioid combination of morphine and oxycodone provides synergistic effects on pain relief and is able to achieve equal or better analgesia at materially lower doses than the active opioid comparator while simultaneously reducing incidence levels of specific side effects."

The goal of the double-blind, placebo-controlled Phase 3 study was to compare four different dosage regimens of Q8003IR in patients with moderate to severe post-surgery pain (bunionectomy) and establish the preferred dose parameters. Secondary endpoints included: (1) efficacy relating to the time to onset of analgesia and the duration of effect from a single oral dose and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

Of the patients receiving 12mg/8mg dose of morphine/oxycodone, 58% reported good to excellent global improvement (as compared to 13% for placebo) and demonstrated the greatest dose-response effect (p<0.0003) in terms of reducing pain intensity scores as well as other measures of analgesic effect.

Post-
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... TEL AVIV, Israel, August 23, 2011 Elbit Imaging ... " Company " ) (NASDAQ: EMITF) , announced today, ... Series B Notes of the Company, that the interest rate borne by ... and ending on February 21, 2012 is 1.56055%. About Elbit ...
... Aug. 23, 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain ... the largest drugstore chain in China based on the ... board of directors has authorized a share repurchase program. ... may repurchase up to US$20 million worth of its ...
Cached Medicine Technology:Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 2Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 3China Nepstar Chain Drugstore Announces Share Repurchase Program 2China Nepstar Chain Drugstore Announces Share Repurchase Program 3
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... 94 per cent of Canadians surveyed said they would ... a specific number of genetic conditions, only 80 per ... screening that would sequence their newborns, genomes.,Most newborns in ... first day or two of life in which a ... and tested for about five to 54 conditions, depending ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3
... provides clues to variations in disease progression , FRIDAY, Sept. ... linked to improvements in the body,s ability to repair itself ... treatments, a U.S. scientist reports. , "Most MS genetic studies ... get MS and others do not," study author Allan Bieber, ...
... Mandatory alcohol testing programs for truck and bus drivers ... in fatal crashes, according to a new study by ... the Johns Hopkins Bloomberg School of Public Health. ... carrier (heavy trucks and buses) drivers and over 83,000 ...
... ... online retailing guide "Internet Retailer". The news story was published on August 7th, 2009 and ... ... Retailer for 40% growth despite doing away with paid searches. The news story sites a ...
... , IRVING, Texas, Sept. 11 ... 643 on its third annual Inc. 5000, an exclusive ranking ... most comprehensive look at the most important segment of the ... rental car service Zipcar, and beverage maker Honest Tea are ...
... GREENSBORO, N.C., Sept. 11 Merz Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has accepted ... Balance. , , Belotero(R) Balance ... that utilizes a cohesive polydensified matrix (CPM(TM)) technology. This ...
... , Office Equipment Manufacturers gain Access to Indoor ... 11 Atlanta-based indoor air quality (IAQ) firm, Air Quality Sciences ... States to perform office equipment emissions testing for Germany,s Blue Angel ... in the world. AQS successfully completed rigorous proficiency verification to ...
Cached Medicine News:Health News:Mandatory alcohol testing for truck and bus drivers reduces alcohol involvement in fatal crashes 2Health News:40% Revenue Growth Nets My1Stop.com a Featured News Story in "Internet Retailer" 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Merz Pharmaceuticals' Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA 2Health News:Air Quality Sciences Achieves Re-Accreditation as the US Indoor Air Quality Testing Partner for Europe's Coveted Blue Angel Program 2Health News:Air Quality Sciences Achieves Re-Accreditation as the US Indoor Air Quality Testing Partner for Europe's Coveted Blue Angel Program 3
... helping you use technology that improves patient ... wireless, simple-to-use BD.id Patient Identification System for ... patient, the specimen container, and the order ... labels only for specimens actually collected, with ...
... Specimen Collections, a Cerner point-of-care solution, ... identification and collection. The solution enhances ... specimen collections process by employing bar-code ... information system integration to prevent potential ...
... CareChek SP Specimen Collection ... Windows CE Pocket PC ... (to perform positive patient ... and an HL7 interface ...
... newest Mediware product, which serves as ... produces a dynamic and complete representation ... clinician orders, medication list, allergies, and ... alerts that increase patient safety. MediMAR ...
Medicine Products: